Objectives: Although cardioprotective effects of telmisartan are well explored, its effects on epigenetic alterations associated with type 2 diabetic (T2D) cardiomyopathy remain unmapped. Thus, the present study was designed to evaluate the potential of esculetin and telmisartan combination to reverse histone posttranslational modifications (PTMs) in curbing T2D cardiomyopathy.
Materials And Methods: T2D was induced by high-fat diet feeding along with low dose of streptozotocin (35 mg/kg, I.P) in male Wistar rats. T2D rats were treated with either telmisartan (10 mg/kg/day, P.O) or esculetin (50 mg/kg/day doses, P.O) or their combination for 2 weeks. Biochemical estimations, vascular reactivity, immunohistochemistry, and western blotting experiments were performed to evaluate the effects of the treatment in T2D cardiomyopathy.
Results: Esculetin and telmisartan combination alleviated the pathological features of T2D cardiomyopathy including metabolic perturbations, morphometric alterations, altered vascular reactivity, increased Keap1 and fibronectin expression more effectively than their respective monotherapy. This is the first report showing that telmisartan attenuates increased level of histone PTMs such as H3K9me2, H3K9Ac, H2AK119Ub, and H2BK120Ub in heart of T2D rats. The combination regimen showed a more significant reduction in augmented histone PTMs associated with T2D cardiomyopathy than their independent treatments.
Conclusions: The present study demonstrates that esculetin and telmisartan combination can be an advanced pharmacological approach to ameliorate T2D cardiomyopathy which could be partially attributed to its ability to reverse the epigenetic alterations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830845 | PMC |
| http://dx.doi.org/10.4103/ijp.IJP_710_16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rising mortality rates linked to type-2 diabetes and obesity in the United States: An observational analysis from 1999 to 2022.
J Diabetes Investig
December 2024
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California Los Angeles, Los Angeles, California, USA.
Background: The prevalence of type 2 diabetes (T2D) and obesity are increasing in the United States. However, population-level data for mortality trends due to T2D and obesity are limited. This study aims to assess these death trends among adults in the United States categorized by sex, race, and geographical location.
View Article and Find Full Text PDFBranched-chain amino acids deficiency promotes diabetic cardiomyopathy by activating autophagy of cardiac fibroblasts.
Theranostics
December 2024
Institute for Developmental and Regenerative Cardiovascular Medicine, MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
More than half of the patients with type II diabetes mellitus (T2D) develop diabetic cardiomyopathy (DCM). Glycemic control alone cannot effectively prevent or alleviate DCM. Herein, we concentrated on the variations in levels of metabolites between DCM and T2D patients without cardiomyopathy phenotype.
View Article and Find Full Text PDFAssociation between subclinical right ventricular alterations and aerobic exercise capacity in type 2 diabetes.
J Cardiovasc Magn Reson
December 2024
Department of Cardiovascular Sciences, University of Leicester, and the National Institute for Health and Care Research Leicester Biomedical Research Centre, Leicester, UK.
Background: Type 2 diabetes (T2D) leads to cardiovascular remodeling, and heart failure has emerged as a major complication of T2D. There is a limited understanding of the impact of T2D on the right heart. This study aimed to assess subclinical right heart alterations and their contribution to aerobic exercise capacity (peak oxygen consumption; peak VO) in adults with T2D.
View Article and Find Full Text PDFSGLT2 inhibitors protect against diabetic cardiomyopathy and atrial fibrillation through a CaMKII independent mechanism.
bioRxiv
September 2024
Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Article Synopsis
- CaMKII is suggested to play a significant role in the heart's protective responses to SGLT2 inhibitors, but the specifics of this relationship are not well understood.
- In a study with type 2 diabetic mice, empagliflozin reduced the likelihood of atrial fibrillation, while both empagliflozin and dapagliflozin helped prevent diabetic heart muscle damage.
- Experiments using a biosensor indicated that blocking CaMKII directly isn't necessary for SGLT2 inhibitors to exert their beneficial effects, implying the action may involve indirect effects on CaMKII or different pathways entirely.
Cardioprotective effects of GPER agonist in ovariectomized diabetic rats: reversing ER stress and structural changes.
Naunyn Schmiedebergs Arch Pharmacol
September 2024
Yazd Neuroendocrine Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
The incidence of diabetic cardiomyopathy (DCM) significantly increases in postmenopausal women, suggesting protective roles of estrogen. Excessive endoplasmic reticulum (ER) stress alters myocardial structure, which plays a crucial role in DCM. The G protein-coupled estrogen receptor (GPER) has been demonstrated to have cardioprotective effects, but it remains unclear whether these effects involve the amelioration of structural changes induced by ER stress.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!